Trial Profile
A 3-year, prospective, multicentre, observational study to evaluate effect of Alemtuzumab on multiple sclerosis-related fatigue, and patient and caregiver-reported outcomes in patients with relapsing-remitting multiple-sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms REALITY
- 01 May 2020 Trial design with baseline patient and caregiver characteristics, presented at the 72nd Annual Meeting of the American Academy of Neurology
- 28 Jul 2017 New trial record